Zonisamide in the Treatment of Essential Tremor
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00616343|
Recruitment Status : Terminated (Principal Investigator left the study site on December 28, 2012.)
First Posted : February 15, 2008
Results First Posted : July 17, 2014
Last Update Posted : July 17, 2014
|Condition or disease||Intervention/treatment||Phase|
|Essential Tremor||Drug: Zonisamide||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Pilot Study of Zonisamide in the Treatment of Essential Tremor|
|Study Start Date :||June 2003|
|Actual Primary Completion Date :||October 2012|
|Actual Study Completion Date :||December 2012|
|Active Comparator: Zonisamide||
100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
Other Name: Zonegran
- Tremor Severity [ Time Frame: 4 weeks ]PI has left the institution and we are unable to accurately assess the data from the remaining records.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00616343
|Principal Investigator:||David M Swope, MD||Loma Linda University|